Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth

Neuland Laboratories posts blockbuster FY26 performance

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million

Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint

Dabur profit jumps 16% as FMCG growth gains pace

Hair care & quick commerce shine

Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth

Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan

Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance

Fabtech Technologies FY26 revenue rises 28% to Rs 431 crore

Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth